Xylem
XYL

Xylem (XYL) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
RBC CapitalMaintainedOutperform$135.00 from $164.00Oct 14, 2026
OppenheimerMaintainedOutperform$150.00 from $158.00Oct 14, 2026
BarclaysMaintainedOverweight$139.00 from $159.00Oct 13, 2026
CitigroupMaintainedBuy$148.00 from $172.00Oct 12, 2026
UBSMaintainedNeutral$112.00 from $138.00Oct 5, 2026
Wolfe ResearchInitiated CoveragePeer Perform—Sep 15, 2026
JefferiesMaintainedBuy$150.00 from $145.00Aug 24, 2026
UBSMaintainedNeutral$138.00 from $135.00Aug 13, 2026
UBSMaintainedNeutral$135.00 from $129.00Jul 30, 2026
BairdMaintainedOutperform$165.00 from $163.00Jul 29, 2026
BarclaysMaintainedOverweight$159.00 from $154.00Jul 29, 2026
RBC CapitalMaintainedOutperform$164.00 from $159.00Jul 29, 2026
MizuhoMaintainedNeutral$130.00 from $124.00Jul 29, 2026
StifelMaintainedBuy$160.00 from $157.00Jul 29, 2026
StifelMaintainedBuy$157.00 from $159.00Jul 20, 2026
RBC CapitalMaintainedOutperform$159.00 from $157.00Jul 16, 2026
JefferiesUpgradedHold → Buy$140.00 from $130.00Jun 25, 2026
StifelMaintainedBuy$159.00 from $163.00Apr 29, 2026
BarclaysMaintainedOverweight$154.00 from $156.00Apr 29, 2026
OppenheimerMaintainedOutperform$158.00 from $160.00Apr 29, 2026

Frequently asked questions

  • What is the latest analyst rating on XYL?

    On Oct 14, 2026, RBC Capital maintained Xylem at Outperform with a price target of $135.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.